OptiNose AS   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Oslo Norway (2000)
Status: No NME R&D (2000)

Organization Overview

First Clinical Trial
2011
NCT01462812
First Marketed Drug
2017
fluticasone (cutivate)
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

OptiNose US | Optinose US Inc. | OPTINOSE US INC

Active Ingredients

Marketed Drugs (1)

fluticasone (cutivate) (2017)

Drugs in Phase 3 Trials (2)

fluticasone (cutivate) (9 trials)

sumatriptan (zecuity) (2 trials)

Drugs in Phase 2 Trials (1)

oxytocin (syntocinon) (2 trials)

Drugs in Phase 1 Trials (1)

nitric oxide (inomax) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Autism Spectrum Disorder (Phase 2)

Autistic Disorder (Phase 2)

Child Development Disorders, Pervasive (Phase 2)

Chronic Disease (Phase 3)

Colorectal Neoplasms (Phase 3)

Headache (Phase 3)

Migraine Disorders (Phase 3)

Nasal Polyps (Phase 3)

Nasopharyngeal Neoplasms (Phase 3)

Polyps (Phase 3)

Respiratory Aspiration (Phase 1)

Sinusitis (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 14
  • # of Trial APIs: 4